Christopher Schott
JPMorgan Chase & Co, Research Division
So good afternoon, everybody. I’m Chris Schott from JPMorgan. And it’s my pleasure to be introducing Amgen today. From the company, we have Chairman and CEO, Bob Bradway. Bob, Happy New Year, and thanks for joining us today.
Looking forward to the presentation. We’re going to do a presentation on stage, and we’ll do a breakout to a Q&A session after that. So, over to you, Bob.
Robert Bradway
Chairman & CEO
Okay. Very good. Thank you, Chris, and good afternoon, everyone. It’s wonderful to see you here and a pleasure to kick off 2026 with all of you. And we’re excited about 2026 at Amgen. We’re see this as a springboard year for us with quite a lot of exciting in particular clinical data being generated at Amgen in 2026.
So let me jump straight in. You’re familiar with the elements of our safe harbor. But just briefly, for those of you who perhaps don’t know Amgen as well as some others, let me just point out that we are active in the 4 general therapeutic areas that you see represented here, and in particular, focused on addressing the diseases, where the unmet medical need remains high, such as those that you see on this slide.
And we address these diseases with first-in-class, best-in-class innovative medicines like those shown on this slide as well as our branded biosimilars. And off the back of these products over the course of the last decade, we’ve delivered very consistent revenue and earnings growth, as you see reflected on this slide.
